Why the study?
Does screening for factor V Leiden and extending anticoagulation for 2 years improve clinical outcomes and cost-effectiveness in patients with a first episode of DVT?
Does screening for factor V Leiden and extending anticoagulation for 2 years improve clinical outcomes and cost-effectiveness in patients with a first episode of DVT?
Screening for factor V Leiden and extending anticoagulation to 2 years is cost-effective after a first DVT, especially for idiopathic cases compliant with warfarin.
Authors
No takes yet. Share an insight, caveat, or question.
Cost-effective to screen for factor V Leiden and extend anticoagulation after first DVT; extends meta-analytic support for genotype-guided secondary prevention.
Pistorio et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: